ir.ibioinc.com
Press Releases :: iBio Inc. (IBIO)
http://ir.ibioinc.com/press-releases
Court Schedules Hearing To Consider Approval Of Settlement Of Derivative Action. January 27, 2017. Another iBio Plague Vaccine Patent Issues. November 21, 2016. IBio Expands Product Development Capacity of cGMP Plant. November 10, 2016. IBio Proprietary Technology Advances Neonatal Respiratory Distress Syndrome Drug Development for South African Biotech Company AzarGen Biotechnologies (Pty) Ltd. September 29, 2016. Implications of Court Decision in Favor of iBio Against Fraunhofer. August 15, 2016.
ir.ibioinc.com
Another iBio Plague Vaccine Patent Issues
http://ir.ibioinc.com/press-releases/detail/74/another-ibio-plague-vaccine-patent-issues
Another iBio Plague Vaccine Patent Issues. November 21, 2016. The new Canadian patent joins iBio's other patents in the Plague Vaccine family in the US (8,404,252, 8,945,580), and also in international markets of interest to iBio and its clients, including Germany, France, Ireland, and United Kingdom. Plague is considered a potential bioterrorism weapon. Bout iBio, Inc. Source: iBio, Inc. Released November 21, 2016.
ir.ibioinc.com
Email Alerts :: iBio Inc. (IBIO)
http://ir.ibioinc.com/email-alerts
Please fill out the form below to receive company press releases via email when they occur. Annual & Quarterly Reports. We respect your privacy. We do not sell, rent, or loan any information to any third party. Any information you give us is held with the utmost care and security, and will be used only in ways to which you have consented.
ir.ibioinc.com
Profile :: iBio Inc. (IBIO)
http://ir.ibioinc.com/profile
Information Regarding Settlement of Derivative Litigation. IBio, Inc. (NYSE MKT: IBIO), a leader in the plant-made pharmaceutical field, develops and offers pharmaceutical product applications using its iBio Technology platform. The iBio Technology platform is a proprietary, transformative technology for the production of biologics including monoclonal antibodies, other therapeutic proteins and vaccines. New York, NY 10022 US. Pharmaceutical Preparation Manufacturing (325412).
ir.ibioinc.com
SEC Filings :: iBio Inc. (IBIO)
http://ir.ibioinc.com/sec-filings
Latest Quarterly or Annual Filing. February 21, 2017. Quarterly report pursuant to Section 13 or 15(d). March 6, 2017. March 11, 2016.
ir.ibioinc.com
Financials :: iBio Inc. (IBIO)
http://ir.ibioinc.com/financials
Condensed Consolidated Balance Sheets - USD ($). Dec 31, 2016. Jun 30, 2016. Accounts receivable - trade. Accounts receivable - unbilled. Prepaid expenses and other current assets. Fixed assets, net of accumulated depreciation. Intangible assets, net of accumulated amortization. Accounts payable (related party of $158 and $200 as of December 31, 2016 and June 30, 2016, respectively). Accrued expenses (related party of $635 and $623 as of December 31, 2016 and June 30, 2016, respectively). URI http:/ asc&...
